pancreatic cancer
Conditions
Interventions
Case series:Drug
Sponsors
SIR Run Run Shaw Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Written informed consent; 2. Aged between 18 and 75 years; 3. pathologically diagnosed as adenocarcinoma; 4. No evidence of distant metastasis; 5. Unresectable locally advanced; 6. According to the RECIST 1.1 , there is at least one measurable lesion; 7. ECOG PS 0 to 1; 8. Adequent organ function; 9. Life expectancy >=3 months; 10. Women of childbearing age must take a pregnancy test (serum or urine) within 7 days before joining the group, and the result is negative, and are willing to take effective contraceptive measures during the entire study period; 11. Tissue samples should be provided for biomarker (such as PD-L1) analysis.
Exclusion criteria
Exclusion criteria: 1. Patients with distant metastases; 2. There are factors that affect oral drugs; 3. Those who are known to be allergic to any of the drugs in the study; 4. Participated in other drug clinical trials within 4 weeks; 5. Those who have received an anti-tumor vaccine or have received a live vaccine within 4 weeks before the first administration of the study drug; 6. History of chemotherapy, radiotherapy and molecular target therapy within 2 weeks; 7. The patient has previously received anti-PD-1, anti-PD-L1 antibody or anti-CTLA-4 antibody treatment; 8. Females who are pregnant, or lactating; 9 Other patients who are considered to be unsuitable for this study by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OS;the rate of R0 resection;ORR;DCR;AEs; | — |
Countries
China
Contacts
Public ContactDefei Hong
SIR Run Run Shaw Hospital, Zhejiang University School of Medicine
Outcome results
None listed